
-
Iovance Biotherapeutics NasdaqGM:IOVA Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Location: 825 Industrial Road, San Carlos, CA, 94070, United States | Website: https://www.iovance.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
305.1M
Cash
359.7M
Avg Qtr Burn
-83.6M
Short % of Float
27.47%
Insider Ownership
0.46%
Institutional Own.
81.38%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMTAGVI™ (Lifileucel) Details Melanoma, Cancer | Approved Quarterly sales | |
Iovance TIL (LN-145) or lifileucel + pembrolizumab + chemotherapy Details Cancer, 1L advanced non-small cell lung carcinoma | Phase 2 Data readout | |
Iovance TIL (LN-145) or lifileucel + relatlimab + nivolumab Details Cancer, 1L advanced melanoma | Phase 2 Data readout | |
Iovance TIL (LN-145) Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
Iovance TIL (LN-145) Details Cancer, Endometrial cancer | Phase 2 Data readout | |
Iovance TIL (LN-145) or lifileucel +/- pembrolizumab Details Cancer, Melanoma | Phase 2 Update | |
Lifileucel Details Cancer, Cervical cancer | Phase 2 Update | |
IOV-4001 Details Cancer, Non-small cell lung carcinoma, Melanoma | Phase 1/2 Data readout | |
IOV-3001 Details Cancer | Phase 1/2 Data readout | |
IOV-2001 Details Cancer, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (post-BTK) | Phase 1 Data readout |